

Imunon, Inc.

(IMNN-NASDAQ)

IMNN: \$10 Million Financing to Advance Phase 3 OVATION 3 Trial

Based on our probability adjusted DCF model that takes into account potential future revenues of IMNN-001 and the PLACCINE technology, IMNN is valued at \$25/share. This model is highly dependent upon continued clinical success of the development candidates and will be adjusted accordingly based on future clinical results.

Current Price (06/05/26) \$2.10
Valuation \$25.00

OUTLOOK

On June 4, 2026, Imunon, Inc. (IMNN) announced a financing that is expected to provide up to \$10 million in aggregate proceeds. The financing includes 250 shares of non-redeemable, non-convertible preferred stock for \$2.5 million and two secured promissory notes in the principal amounts of \$2.72 million and \$5.0 million. Importantly, there are no warrants or other dilutive overhangs. The financing will be used in part by the company to continue enrolling the ongoing Phase 3 OVATION 3 trial that is testing IMNN-001 in women with newly diagnosed advanced ovarian cancer.

SUMMARY DATA

52-Week High \$24.90
52-Week Low \$2.10
One-Year Return (%) -88.49
Beta 1.95
Average Daily Volume (sh) 49,931

Shares Outstanding (mil) 4
Market Capitalization (\$mil) \$9
Short Interest Ratio (days) N/A
Institutional Ownership (%) 4
Insider Ownership (%) 3

Annual Cash Dividend \$0.00
Dividend Yield (%) 0.00

5-Yr. Historical Growth Rates
Sales (%) N/A
Earnings Per Share (%) N/A
Dividend (%) N/A

P/E using TTM EPS N/A
P/E using 2026 Estimate -0.6
P/E using 2027 Estimate -1.0

Risk Level
Type of Stock
Industry
Average
Small-Blend
Med-Biomed/Gene

ZACKS ESTIMATES

Revenue (In millions of \$)

	Q1 (Mar)	Q2 (Jun)	Q3 (Sep)	Q4 (Dec)	Year (Dec)
2025	0.0 A	0.0 A	0.0 A	0.0 A	0.0 A
2026	0.0 A	0.0 E	0.0 E	0.0 E	0.0 E
2027					0.0 E
2028					0.0 E

Earnings per Share

	Q1 (Mar)	Q2 (Jun)	Q3 (Sep)	Q4 (Dec)	Year (Dec)
2025	-\$4.23 A	-\$2.15 A	-\$1.16 A	-\$1.28 A	-\$6.83 A
2026	-\$0.84 A	-\$0.99 E	-\$0.87 E	-\$0.64 E	-\$3.25 E
2027					-\$2.00 E
2028					-\$1.84 E

WHAT'S NEW

Business Update

\$10 Million Financing to Advance Phase 3 OVATION 3 Trial

On May 4, 2026, Imunon, Inc. (IMNN) announced a uniquely structured financing expected to provide up to \$10 million in gross proceeds, helping to bolster the company's balance sheet as it advances enrollment in the pivotal Phase 3 OVATION 3 study of IMNN-001 in newly diagnosed advanced ovarian cancer. The financing consists of \$2.5 million of non-convertible preferred stock and \$7.72 million of secured promissory notes with 18-month maturities. Unlike many financings for small-cap biotechnology companies, the transaction does not include warrants and avoids the substantial discounts to market that often accompany traditional equity offerings.

At closing, Imunon received \$10 million from the investor, with approximately \$5 million immediately available to support operations and the remaining \$5 million held as collateral backing a secured note structure. Importantly, the company can progressively unlock portions of the collateralized funds as it repays or redeems portions of the financing, creating a flexible source of future liquidity without requiring additional capital raises. This structure effectively provides Imunon with access to capital while preserving optionality as clinical milestones are achieved.

Management emphasized that the financing was specifically designed to support continued enrollment in OVATION 3 while maintaining a disciplined approach to capital management. The additional liquidity reduces near-term financing pressure and provides the company with greater flexibility to execute its clinical strategy from a stronger balance sheet position.

From a shareholder perspective, the transaction compares favorably to a conventional equity raise. The preferred shares are non-convertible, eliminating a potential source of future share issuance, while the absence of warrant coverage reduces long-term dilution overhang. In addition, the financing structure allows management to access additional capital through the release of collateralized funds as certain repayment thresholds are met, potentially reducing the need for future equity issuance.

Imunon recently announced updated data from the Phase 2 OVATION 2 trial of IMNN-001 in women with newly diagnosed ovarian cancer. Previously, the company had reported a 11.1-month increase in overall survival (OS) (40.5 vs. 29.4 months) in the IMNN-001 treatment arm compared to standard of care (SoC) chemotherapy alone. The updated data shows a median 14.7-month increase in OS (45.1 vs. 30.4 months) in women in the IMNN-001 treatment arm compared to SoC chemotherapy. In addition, for women being treated with IMNN-001, SoC chemotherapy, and poly ADP-ribose polymerase (PARP) inhibitors, the increase in median OS is now 24.2 months (65.6 vs. 41.4 months) compared to SoC chemotherapy and PARP inhibitors.

These results continue to show the positive impact that IMNN-001 is having on patients with newly diagnosed advanced ovarian cancer. There have been few notable advancements in the SoC for ovarian cancer in the past 30+ years, thus the now 14.7-month increase in OS, if it can be replicated in the ongoing Phase 3 OVATION 3 trial, could lead to a paradigm shift in how these patients are treated. Lastly, the increase in OS was accomplished with a favorable safety and tolerability profile and is another reason why IMNN-001 has received such a positive response from the medical community.

Conclusion


Overall, we view the recent financing as an important bridge that extends IMUNON's financial flexibility during a critical phase of development. While the transaction introduces modest debt obligations, its non-dilutive features, lack of warrants, and company-controlled access to capital make it substantially more shareholder-friendly than many alternative financing options available to development-stage biotechnology companies. As we had already accounted for financings in our model, our valuation remains at \$25 per share.

PROJECTED FINANCIALS

Imunon, Inc.	2025 A	Q1 A	Q2 E	Q3 E	Q4 E	2026 E	2027 E	2028 E
IMNN-001	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0
IMNN-101	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0
Other Income	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0
Total Revenues	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0
CoGS	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0
R&D	\$7.8	\$2.3	\$2.3	\$2.4	\$2.4	\$9.4	\$10.0	\$11.0
SG&A	\$6.9	\$2.0	\$1.9	\$2.0	\$2.1	\$8.0	\$8.2	\$8.4
Operating Income	(\$14.7)	(\$4.3)	(\$4.2)	(\$4.4)	(\$4.5)	(\$17.4)	(\$18.2)	(\$19.4)
<i>Operating Margin</i>	-	-	-	-	-	-	-	-
Interest & Other Income	\$0.2	\$0.1	\$0.0	\$0.0	\$0.0	\$0.2	\$0.2	\$0.2
Pre-Tax Income	(\$14.5)	(\$4.2)	(\$4.2)	(\$4.4)	(\$4.5)	(\$17.2)	(\$18.0)	(\$19.2)
Taxes & Other	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$1.0
<i>Tax Rate</i>	0%	0%	0%	0%	0%	0%	0%	100%
Net Income	(\$14.5)	(\$4.2)	(\$4.2)	(\$4.4)	(\$4.5)	(\$17.2)	(\$18.0)	(\$20.2)
Reported EPS	(\$6.83)	(\$0.84)	(\$0.99)	(\$0.87)	(\$0.64)	(\$3.25)	(\$2.00)	(\$1.84)
Weighted Shares Outstanding	2.1	5.0	4.2	5.0	7.0	5.3	9.0	11.0

Source: Zacks Investment Research, Inc. David Bautz, PhD

HISTORICAL STOCK PRICE



Source: Zacks Small Cap Research

DISCLOSURES

The following disclosures relate to relationships between Zacks Small-Cap Research ("Zacks SCR"), a division of Zacks Investment Research ("ZIR"), and the issuers covered by the Zacks SCR Analysts in the Small-Cap Universe.

ANALYST DISCLOSURES

I, David Bautz, PhD, hereby certify that the view expressed in this research report accurately reflect my personal views about the subject securities and issuers. I also certify that no part of my compensation was, is, or will be, directly or indirectly, related to the recommendations or views expressed in this research report. I believe the information used for the creation of this report has been obtained from sources I considered to be reliable, but I can neither guarantee nor represent the completeness or accuracy of the information herewith. Such information and the opinions expressed are subject to change without notice.

INVESTMENT BANKING AND FEES FOR SERVICES

Zacks SCR does not provide investment banking services nor has it received compensation for investment banking services from the issuers of the securities covered in this report or article.

Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm engaged by the issuer for providing non-investment banking services to this issuer and expects to receive additional compensation for such non-investment banking services provided to this issuer. The non-investment banking services provided to the issuer includes the preparation of this report, investor relations services, investment software, financial database analysis, organization of non-deal road shows, and attendance fees for conferences sponsored or co-sponsored by Zacks SCR. The fees for these services vary on a per-client basis and are subject to the number and types of services contracted. Fees typically range between ten thousand and fifty thousand dollars per annum. Details of fees paid by this issuer are available upon request.

POLICY DISCLOSURES

This report provides an objective valuation of the issuer today and expected valuations of the issuer at various future dates based on applying standard investment valuation methodologies to the revenue and EPS forecasts made by the SCR Analyst of the issuer's business. SCR Analysts are restricted from holding or trading securities in the issuers that they cover. ZIR and Zacks SCR do not make a market in any security followed by SCR nor do they act as dealers in these securities. Each Zacks SCR Analyst has full discretion over the valuation of the issuer included in this report based on his or her own due diligence. SCR Analysts are paid based on the number of companies they cover. SCR Analyst compensation is not, was not, nor will be, directly or indirectly, related to the specific valuations or views expressed in any report or article.

ADDITIONAL INFORMATION

Additional information is available upon request. Zacks SCR reports and articles are based on data obtained from sources that it believes to be reliable, but are not guaranteed to be accurate nor do they purport to be complete. Because of individual financial or investment objectives and/or financial circumstances, this report or article should not be construed as advice designed to meet the particular investment needs of any investor. Investing involves risk. Any opinions expressed by Zacks SCR Analysts are subject to change without notice. Reports or articles or tweets are not to be construed as an offer or solicitation of an offer to buy or sell the securities herein mentioned.

CANADIAN COVERAGE

This research report is a product of Zacks SCR and prepared by a research analyst who is employed by or is a consultant to Zacks SCR. The research analyst preparing the research report is resident outside of Canada, and is not an associated person of any Canadian registered adviser and/or dealer. Therefore, the analyst is not subject to supervision by a Canadian registered adviser and/or dealer, and is not required to satisfy the regulatory licensing requirements of any Canadian provincial securities regulators, the Investment Industry Regulatory Organization of Canada and is not required to otherwise comply with Canadian rules or regulations.